日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)

根据IPSS-R对骨髓增生异常综合征(MDS)患者的中危核型进行细化

Nachtkamp, K; Schulz, F; Kasprzak, A; Strupp, C; Hildebrandt, B; Pfeilstöcker, M; Valent, P; Blum, B; Giagounidis, A; Götze, K; Flatten, V; Dietrich, S; Kobbe, G; Haase, D; Gattermann, N; Germing, U

Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study

不同类型癌症或血液系统恶性肿瘤患者焦虑和抑郁的患病率:一项横断面研究

Zeilinger, E L; Oppenauer, C; Knefel, M; Kantor, V; Schneckenreiter, C; Lubowitzki, S; Krammer, K; Popinger, C; Kitta, A; Kum, L; Adamidis, F; Unseld, M; Masel, E K; Füreder, T; Zöchbauer-Müller, S; Bartsch, R; Raderer, M; Prager, G; Krauth, M T; Sperr, W R; Porpaczy, E; Staber, P B; Valent, P; Gaiger, A

Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter

核心结合因子白血病劫持T细胞易感PU.1反义启动子

van der Kouwe, E; Heller, G; Czibere, A; Pulikkan, J A; Agreiter, C; Castilla, L H; Delwel, R; Di Ruscio, A; Ebralidze, A K; Forte, M; Grebien, F; Heyes, E; Kazianka, L; Klinger, J; Kornauth, C; Le, T; Lind, K; Barbosa, I A M; Pemovska, T; Pichler, A; Schmolke, A-S; Schweicker, C M; Sill, H; Sperr, W R; Spittler, A; Surapally, S; Trinh, B Q; Valent, P; Vanura, K; Welner, R S; Zuber, J; Tenen, D G; Staber, P B

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

治疗相关性骨髓增生异常综合征需要进行特定的诊断亚分类和风险分层——一种针对治疗相关性骨髓增生异常综合征患者的分类方法。

Kuendgen, A; Nomdedeu, M; Tuechler, H; Garcia-Manero, G; Komrokji, R S; Sekeres, M A; Della Porta, M G; Cazzola, M; DeZern, A E; Roboz, G J; Steensma, D P; Van de Loosdrecht, A A; Schlenk, R F; Grau, J; Calvo, X; Blum, S; Pereira, A; Valent, P; Costa, D; Giagounidis, A; Xicoy, B; Döhner, H; Platzbecker, U; Pedro, C; Lübbert, M; Oiartzabal, I; Díez-Campelo, M; Cedena, M T; Machherndl-Spandl, S; López-Pavía, M; Baldus, C D; Martinez-de-Sola, M; Stauder, R; Merchan, B; List, A; Ganster, C; Schroeder, T; Voso, M T; Pfeilstöcker, M; Sill, H; Hildebrandt, B; Esteve, J; Nomdedeu, B; Cobo, F; Haas, R; Sole, F; Germing, U; Greenberg, P L; Haase, D; Sanz, G

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells

药物诱导的STAT5磷酸化抑制可克服肿瘤性肥大细胞的耐药性。

Peter, B; Bibi, S; Eisenwort, G; Wingelhofer, B; Berger, D; Stefanzl, G; Blatt, K; Herrmann, H; Hadzijusufovic, E; Hoermann, G; Hoffmann, T; Schwaab, J; Jawhar, M; Willmann, M; Sperr, W R; Zuber, J; Sotlar, K; Horny, H-P; Moriggl, R; Reiter, A; Arock, M; Valent, P

Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study

鼻内给予过敏原可增加特异性 IgE 水平,而鼻内给予奥马珠单抗则不会增加血清 IgE 水平——一项初步研究

Eckl-Dorna, J; Fröschl, R; Lupinek, C; Kiss, R; Gattinger, P; Marth, K; Campana, R; Mittermann, I; Blatt, K; Valent, P; Selb, R; Mayer, A; Gangl, K; Steiner, I; Gamper, J; Perkmann, T; Zieglmayer, P; Gevaert, P; Valenta, R; Niederberger, V

Midostaurin: a magic bullet that blocks mast cell expansion and activation

米哚妥林:一种能阻断肥大细胞增殖和活化的神奇药物

Valent, P; Akin, C; Hartmann, K; George, T I; Sotlar, K; Peter, B; Gleixner, K V; Blatt, K; Sperr, W R; Manley, P W; Hermine, O; Kluin-Nelemans, H C; Arock, M; Horny, H-P; Reiter, A; Gotlib, J

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors

NDEL1-PDGFRB融合基因在伴有嗜酸性粒细胞增多症的髓系恶性肿瘤中与酪氨酸激酶抑制剂耐药性相关

Byrgazov, K; Kastner, R; Gorna, M; Hoermann, G; Koenig, M; Lucini, C B; Ulreich, R; Benesch, M; Strenger, V; Lackner, H; Schwinger, W; Sovinz, P; Haas, O A; van den Heuvel-Eibrink, M; Niemeyer, C M; Hantschel, O; Valent, P; Superti-Furga, G; Urban, C; Dworzak, M N; Lion, T

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

尼洛替尼诱发的血管病变:血管内皮细胞被确定为主要靶点

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Hoermann, G; Grebien, F; Eisenwort, G; Schgoer, W; Herndlhofer, S; Kaun, C; Theurl, M; Sperr, W R; Rix, U; Sadovnik, I; Jilma, B; Schernthaner, G H; Wojta, J; Wolf, D; Superti-Furga, G; Kirchmair, R; Valent, P

O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.

STAT5 的 O-GlcNAc 化控制着 STAT5 依赖性恶性肿瘤中的酪氨酸磷酸化和致癌转录

Freund P, Kerenyi M A, Hager M, Wagner T, Wingelhofer B, Pham H T T, Elabd M, Han X, Valent P, Gouilleux F, Sexl V, Krämer O H, Groner B, Moriggl R